Besifloxacin ophthalmic solution regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously to recommend approval for 0.6% besifloxacin ophthalmic suspension to treat bacterial conjunctivitis. The PDUFA date is undi...